Triax Pharmaceuticals, Providers of the No. 1 Prescribed Mid-Potency Corticosteroid Brand, Introduce a New Size of Locoid Lotion 0.1%

Share Article

Launched at the 67th Annual American Academy of Dermatology Meeting

Triax Pharmaceuticals introduces a new 4 oz. size Locoid Lotion

Locoid Lotion has unique properties, and is an ideal product for certain hard to treat areas such as the chest, the arms, and the legs.

Atopic dermatitis (AD) is very common in the United States. It affects nearly 15 million people (1% to 3% of adults and 10% to 20% of children).1, and accounts for 10 to 20 percent of all visits to dermatologists. The key symptom is pruritus (itching), leading to the description of AD as "the itch that rashes." Topical corticosteroids have become the cornerstone of treatment for a variety of inflammatory dermatoses, including atopic dermatitis (AD), eczema, and psoriasis.2

Triax Pharmaceuticals, the marketers of Locoid Lipocream® (hydrocortisone butyrate 0.1%) the leading mid-potency corticosteroid brand, introduces a new 4 oz. size of its recently launched Locoid® Lotion.

Launched at the American Academy of Dermatology (AAD) meeting in San Francisco, Locoid® Lotion (hydrocortisone butyrate 0.1%) contains a moisturizing vehicle to cover larger areas and hairy areas of affected skin with an elegant, non-greasy application; and is indicated to treat mild-to-moderate atopic dermatitis in patients as young as 3 months of age2. Locoid Lotion and Locoid Lipocream have been formulated with high concentration of barrier-enhancing lipids. This unique feature provides skin barrier restorative properties for a wide range of patients. Locoid Lotion 0.1% may provide physicians with a formulation that is easier to apply to extensive areas of disease than creams or ointments.

Locoid Lotion (hydrocortisone butyrate 0.1% lotion) is the only class 5 corticosteroid indicated for patients with AD ages 3 months of age and older. It has been proven to provide significant relief of all AD symptoms in pediatric and adult patients2, 3. By the conclusion of one study, 89% of patients had symptoms of skin-barrier disruption eliminated or reduced to mild. By Day 8, average pruritis-symptom scores were reduced to less than mild.

Topical Corticosteroids are widely used in the treatment of mild to moderate inflammatory skin diseases. Locoid Lotion has a wide range of benefits which include the following:

  • A new 4 oz. size for larger surface areas.
  • Easy to apply and rapidly absorbed, which in turn, makes it easy to spread over affected areas, including affected areas that are large and/or hairy. The cosmetic acceptability promotes patient compliance4.
  • Promotes hydration and enhances penetration of the active drug.
  • Non-halogenated, which allows for low risk of potential side effects.
  • Unlike the majority of topical corticosteroids, Locoid Lotion contains no irritants such as propylene glycol, lanolin, or imidurea and is formulated in a non-irritating and fragrance-free base.

Dr. Adelaide Hebert, a dermatologist based in Houston, Texas remarks, "Locoid Lotion has unique properties, and is an ideal product for certain hard to treat areas such as the chest, the arms, and the legs."

Locoid Lotion is available nationwide in a 2 fl. oz. or a 4 fl. oz. bottle.

Reversible HPA axis suppression may occur with the potential for corticosteroid insufficiency. Consider periodic evaluations for HPA axis suppression if applied to large surface areas or used under occlusion. Systemic effects of topical corticosteroids may also include manifestations of Cushing's syndrome, hyperglycemia, and glucosuria. Pediatric patients may be more susceptible to systemic toxicity due to their large skin surface-to-body-mass ratios. Initiate appropriate therapy if a concomitant skin infection develops. Discontinue use if irritation develops.

About Triax Pharmaceuticals, LLC
Triax Pharmaceuticals is a specialty pharmaceutical company with integrated sales, marketing, and development expertise that markets a portfolio of branded dermatological products. Triax focuses on marketing dermatology products in the United States. Triax sales force is comprised of dermatology sales professionals nationwide.

In addition to industry leader Locoid Lipocream and new Locoid Lotion, Triax Pharmaceuticals also markets the following products:

Tretin-X® (tretinoin) Kit is available in 0.025% cream, 0.05% cream, 0.1% cream, 0.01% gel, and 0.025% gel. Each kit contains Tretinoin cream or gel along with two cosmetic products included at no additional cost to the patient: T3™ Foaming Cleanser and T3 Soothing Moisturizer.

Minocin® (minocycline HCl) Pellet-filled Capsules Professional Acne Care (P.A.C.). The Minocin PAC system contains a 60 count bottle of Minocin Pellet-Filled Capsules (50 mg or 100 mg) and three skincare products (at no additional cost to the patient).

For more information on Locoid Lotion or other Triax products, please contact Peter Volk or Aleen Hosdaghian of Triax Pharmaceuticals, LLC, 908.372.0500. See http://www.locoidlotion.com and http://www.locoid.com for full prescribing information.

1 http://www.niams.nih.gov/Health_Info/Atopic_Dermatitis/default.asp#link_b
2 Matheson R, Kempers S, Breneman D, et al. Hydrocortisone butyrate 0.1% lotion in the treatment of atopic dermatitis in pediatric subjects. J Drugs Dermatol. 2008;7:266-271.
3 Data on file.
4 Fowler JF Jr. Hydrocortisone butyrate 0.1% cream in the treatment of chronic dermatitis. Cutis 2005;75:125-131.

©2009 Triax Pharmaceuticals, LLC. All rights reserved. Locoid and Locoid Lipocream are registered trademarks of Astellas Pharma Europe B.V. Licensed to Triax Pharmaceuticals, LLC. LLT-050801

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Peter Volk

Aleen Hosdaghian
Triax Pharmaceuticals
908-372-0500
Email >
Visit website